Summary
1.36 0.00(0.00%)09/05/2024
Atossa Genetics Inc. (ATOS)
Atossa Genetics Inc. (ATOS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.74 | -0.73 | 18.26 | 3.03 | 33.33 | 76.62 | -31.66 | -99.84 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.36 | |
| Open | 1.37 | |
| High | 1.37 | |
| Low | 1.33 | |
| Volume | 306,091 | |
| Change | 0.01 | |
| Change % | 0.74 | |
| Avg Volume (20 Days) | 475,947 | |
| Volume/Avg Volume (20 Days) Ratio | 0.64 | |
| 52 Week Range | 0.62 - 2.31 | |
| Price vs 52 Week High | -41.13% | |
| Price vs 52 Week Low | 119.35% | |
| Range | -0.73 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 171 | |
| EBIDTA | -31,354,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 4.67 | |
| Book Value | 0.7260 | |
| Earnings Per Share | -0.2400 | |
| EPS Estimate Current Quarter | -0.0600 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.2700 | |
| EPS Estimate Next Year | -0.2900 | |
| Diluted EPS (TTM) | -0.2400 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.1784 | |
| Return on equity (TTM) | -0.2880 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.2991 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | -3.8527 | |
| Shares | ||
| Shares Outstanding | 125,304,000 | |
| Shares Float | 117,480,078 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.09 | |
| Insider (%) | 0.06 | |
| Institutions (%) | 19.21 | |
09/03 10:40 EST - zacks.com
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
09/03 08:30 EST - globenewswire.com
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually.
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SEATTLE, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event, scheduled for September 9-11, 2024, will be held both in-person and virtually.
08/30 13:01 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
08/28 08:30 EST - globenewswire.com
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
08/21 11:30 EST - globenewswire.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Seattle, WA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SEATTLE, August 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient has been dosed in their clinical trial evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Seattle, WA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SEATTLE, August 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ (QLHC), today announced the first patient has been dosed in their clinical trial evaluating Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, as a neoadjuvant treatment in high-risk women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in oncology with a focus on breast cancer.
08/20 08:30 EST - globenewswire.com
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
08/12 08:30 EST - globenewswire.com
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended June 30, 2024, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on women's breast cancer and other breast conditions.
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended June 30, 2024, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on women's breast cancer and other breast conditions.
07/22 08:30 EST - globenewswire.com
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
07/11 10:41 EST - zacks.com
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.
07/11 07:00 EST - investorplace.com
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.
07/03 09:45 EST - investorplace.com
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
By now, you're well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here's what the U.S. SEC says: “ Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them.
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
By now, you're well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here's what the U.S. SEC says: “ Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them.
07/02 16:35 EST - proactiveinvestors.com
Atossa Therapeutics names Heather Rees as CFO
Atossa Therapeutics Inc (NASDAQ:ATOS) has appointed Heather Rees as its new Chief Financial Officer (CFO). The move marks a promotion for Rees, who previously served as the company's senior vice president of finance and principal accounting officer.
Atossa Therapeutics names Heather Rees as CFO
Atossa Therapeutics Inc (NASDAQ:ATOS) has appointed Heather Rees as its new Chief Financial Officer (CFO). The move marks a promotion for Rees, who previously served as the company's senior vice president of finance and principal accounting officer.
07/02 16:15 EST - globenewswire.com
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company's new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company's new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa's Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
06/28 08:30 EST - globenewswire.com
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. The study is investigating the combination as a neoadjuvant treatment in women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. The study is investigating the combination as a neoadjuvant treatment in women with newly diagnosed Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
06/17 08:30 EST - globenewswire.com
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
06/07 07:30 EST - investorplace.com
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed.
06/06 10:41 EST - zacks.com
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Here is how Atossa Genetics Inc. (ATOS) and Ocugen (OCGN) have performed compared to their sector so far this year.
06/05 08:30 EST - globenewswire.com
Atossa to Present at the Sidoti Small-Cap Investor Conference
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
Atossa to Present at the Sidoti Small-Cap Investor Conference
SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
05/28 09:37 EST - proactiveinvestors.co.uk
Atossa Therapeutics to support AI-based breast cancer risk study
Atossa Therapeutics Inc (NASDAQ:ATOS). (Nasdaq: ATOS) has announced its support for the SMART (Stockholm MAmmography Risk stratified Trial) study, a new Phase 2 clinical trial aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model.
Atossa Therapeutics to support AI-based breast cancer risk study
Atossa Therapeutics Inc (NASDAQ:ATOS). (Nasdaq: ATOS) has announced its support for the SMART (Stockholm MAmmography Risk stratified Trial) study, a new Phase 2 clinical trial aimed at validating an innovative artificial intelligence-driven breast cancer risk assessment model.